Zoetis Inc. (ZTS): Price and Financial Metrics
Zoetis Inc. (ZTS)
Today's Latest Price: $162.57 USD
Updated Jan 19 7:00pm
Add ZTS to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 239 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
ZTS Stock Summary
- ZTS has a higher market value than 97.14% of US stocks; more precisely, its current market capitalization is $76,784,268,838.
- With a one year PEG ratio of 394.53, Zoetis Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 90.69% of US stocks.
- Price to trailing twelve month operating cash flow for ZTS is currently 38.59, higher than 87.77% of US stocks with positive operating cash flow.
- If you're looking for stocks that are quantitatively similar to Zoetis Inc, a group of peers worth examining would be BDX, CI, SYK, ABB, and MDLZ.
- Visit ZTS's SEC page to see the company's official filings. To visit the company's web site, go to www.zoetis.com.
ZTS Stock Price Chart Interactive Chart >
ZTS Price/Volume Stats
| Current price | $162.57 | 52-week high | $176.64 |
| Prev. close | $161.56 | 52-week low | $90.14 |
| Day low | $161.25 | Volume | 1,464,100 |
| Day high | $163.95 | Avg. volume | 1,791,755 |
| 50-day MA | $162.94 | Dividend yield | 0.5% |
| 200-day MA | $150.26 | Market Cap | 77.26B |
Zoetis Inc. (ZTS) Company Bio
Zoetis Inc. discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. The company was founded in 1952 and is based in Florham Park, New Jersey.
ZTS Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $162.57 | $61.16 | -62% |
We started the process of determining a valid price forecast for Zoetis Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Zoetis Inc ranked in the 29th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. The most interesting components of our discounted cash flow analysis for Zoetis Inc ended up being:
- Interest coverage, a measure of earnings relative to interest payments, is 9.79 -- which is good for besting 70.06% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
- ZTS's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than 35.41% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -63% |
| 1% | -63% |
| 2% | -62% |
| 3% | -62% |
| 4% | -61% |
| 5% | -61% |
HAPP, PCRX, DYNT, HOLX, and LNTH can be thought of as valuation peers to ZTS, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...